Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma

In this podcast episode, listen to myeloma experts Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer audience questions from a live CCO Webinar on available and emerging therapeutic strategies for patients with early and late relapsed/refractory multiple myeloma.

This podcast is intended for clinicians practicing medicine outside of the United States.

Released: September 3, 2020

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and  Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:

  • Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial
  • Selecting therapy for a patient with lenalidomide-refractory disease at first relapse
  • How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms
  • Key findings from the DREAMM2 trial on belantamab mafodotin
  • Monitoring and management strategies for ocular toxicity with belantamab mafodotin

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/new tx rr mm

Acknowledgements

Provided by Clinical Care Options, LLC, in partnership with Clinical Care Options Global B.V.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Related Content

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Download these expert-selected slides on later-stage relapsed/refractory myeloma to help manage your patients, from Clinical Care Options (CCO).

Paul G. Richardson, MD Released: September 22, 2022

See key clinical insights fast, with this short slideset from CCO on relapsed/refractory myeloma, from Clinical Care Options (CCO).

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings